Alto Neuroscience

Alto Neuroscience develops biology-driven medicines for neuropsychiatric conditions, aiming to help patients get better faster. The company states that it measures brain biology to predict clinical response and identify patients most likely to benefit from its drug candidates. Its clinical-stage drug candidates are designed to target core brain processes, with an initial focus on major depressive disorder, bipolar depression, and schizophrenia. Alto was founded in 2019 by Dr. Amit Etkin after over a decade of clinical research in his laboratory at Stanford, and it harnesses 15 years of neuroscience research and clinical data to match the right patient with the right treatment.

Alto Neuroscience was founded in 2019 by Dr. Amit Etkin after over a decade of clinical research in his laboratory at Stanford. A former tenured professor, Dr. Etkin founded the company to develop precision treatments for people with neuropsychiatric conditions. The company states that it harnesses 15 years of field-leading neuroscience research and clinical data to match the right patient with the right treatment.

Pioneers in precision psychiatry; disrupting the trial-and-error approach to treating neuropsychiatric conditions.

1. 1Leading Innovation in Psychiatric Treatment | Alto Neurosciencealtoneuroscience.com
2. 2Pioneers in Precision Psychiatry | About Alto Neurosciencealtoneuroscience.com
3. 3Our Precision Psychiatry Platform | Alto Neurosciencealtoneuroscience.com